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Cancer of the kidney is associated with a bewildering array of extrarenal symptoms, and conversely,
tumors far removed from the kidney produce intriguing renal functional abnormalities.
A variety of extrarenal complications are seen
with hypernephromas, most of which rarely accompany Wilms tumors which grow rapidly and generally
occur before the age of 7. Wilms tumors are quite
susceptible to radiation therapy and surgery, and are
to be strongly suspected when hypertension and an
abdominal mass are found in a small child. Unless
treated, they rapidly cause death and usually leave
little opportunity for the patient to develop the striking extrarenal manifestations seen with hypernephroma.
Among the fascinating complications of hypernephromas (Table l) is first, the extremely slow
growth rate of a sizable minority of them. I have seen
patients known to have hematuria for up to three
years prior to the time that the tumor was found and,
on reviewing the intravenous pyelogram done at the
onset of hematuria, seen evidence that a renal mass
had been present all along . Those tumors which do
grow slowly may result in generalized amyloidosis
both in the kidney and elsewhere. Another peculiarity
of the hypernephroma, which is almost unique to this
tumor, is the disappearance of metastases once the
primary tumor has been removed. In only a few
instances has there been histologic evidence that the
"metastatic" lesions were indeed derived from a renal
cell carcinoma. Nevertheless, the phenomenon of
spontaneous regression of metastases seems well esThis paper is supported by USPHS Grant #AM 20132.
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tablished and offers at least a gleam of hope for those
in whom pulmonary metastases are found .
Perhaps equally remarkable is the finding of distant metastases many years after a renal cell carcinoma is removed surgically . The longest recorded
survival between a diagnosis of renal carcinoma and
the eventual death of a patient whose neoplasm was
considered inoperable and left in place is 37 years. 1
Many patients have been reported to develop metastases 5, JO, and even 25 years after the resection of a
hypernephroma. I have seen a patient who developed
"solitary" metastases sequentially over a 19-year period before he succumbed. Unfortunately, while such
cases stand out, metastases appear earlier in most
patients and lead to death within two years in one
third of patients.
Renal cell carcinoma also tends to extend via the
renal vein lumen into the inferior vena cava. Such a
circumstance is reported to occur in almost 10% of
patients with hypernephromas, 2 and a substantial
proportion of these tumors extends all the way up the
vena cava into the right atrium. 3 The extending tumor usually is restricted to the venous lumen without
penetration of the vessel wall and, as a result, is
generally removable in its entirety. Surprisingly, such
vascular involvement a lone does not appear greatly
to alter the prognosis at 5 or l O years, 4 and extraction
of the tumor mass is often both possible and desirable.
Fever, unexplained by infection, is a common
concomitant of hypernephroma. Melicow and Uson~
have reported that 16% of 577 cases of renal carcinoma presented with fever, often with weakness, anorexia, and weight loss, without any urologic symptoms whatsoever. A much higher percentage
combined these systemic manifestations with hematuria, an abdominal mass, or pain . Thus, it is not
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TABLE I
Peculiarities of Hypernephromas
1.
2.
3.
4.
5.
6.
7.
8.
9.

Slow growth frequent
Disappearance of metastases (rare)
Cause of occult fever (FUO)
Renal vein/ vena cava spread
Nonmetastatic hepatic dysfunction
Benign nephrohepatom egaly
Polycythemia, leukemoid reaction , eosinophilia
Heart fai'lure
Sponta neous rupture of kidney

uncommon for patients with hypernephroma to present with "fever of unknown origin" and a baffling
clinical picture. The fever may be low-grade and constant or intermittent and hectic, temperatures reaching 39.5 C (103 F) and higher.
First described in 1961,6 a syndrome of nonmetastatic hepatic dysfunction (NHDS) accompanies
the systemic abnormalities mentioned above in some
10% of patients with hypernephromas, 7 and presents
with hepatomegaly which differs both functionally
and histologically from the benign hepatomegaly frequently encountered with such tumors.a Here, biochemical abnormalities include elevated serum alkaline phosphatase concentrations, hypoalbuminemia,
and hyperglobulinemia. Liver biopsy may reveal nonspecific inflammatory infiltrates, fatty deposition, degenerative and regenerative changes of liver cells, and
areas of focal necrosis.a The syndrome may mimic
metastatic disease of the liver from which it must be
distinguished in that it is potentially reversible after
nephrectomy is performed; recognition of NHDS
may suggest a diagnosis of previously unrecognized
hypernephroma.
Reviews of polycythemia generally include hypernephroma in the list of causes, but in fact, polycythemia has been associated with this tumor in only
1% to 4% of most reported series. 10 Actually, anemia
is more the rule than the exception whether or not the
patient has had significant hematuria. 11 Eosinophilia,
thrombocytosis, leukocytosis, and even leukomoid
reactions occur in significant association with hypernephromas.12 Coupled with fever of unknown origin,
or alone, such findings may present vexing diagnostic
problems.
As in many other types of malignancy, thrombophlebitis accompanies renal cell carcinoma with
some frequency. Varicocele, particularly when on the
right, may be the first clue to the existence of a renal
tumor.

Hypertension is recorded in more than 20% of
the patients with hypernephroma and in some cases,
at least, the hypertension has been cured by nephrectomy .5 In others, hypertension is not surgically correctable, and it is difficult to be sure that the tumor
was causally related. The renal tumor most clearly
associated with hypertension is the "juxtaglomerular
cell" tumor. Neoplastically benign, this growth, originating in macula densa tissue, produces huge
amounts of renin with resultant secondary hyperaldosteronism and the complications attendant upon
that condition. It is mentioned here as a rare but
fascinating renal tumor which produces signs and
symptoms which may erroneously suggest the existence of renal arterial stenosis or venous obstruction
secondary to the spread of renal adenocarcinoma or
the hyperreninism sometimes associated with Wilms
tumors.13
Uncommon but life-threatening vascular complications of hypernephromas include high-output
congestive heart failure and spontaneous rupture of
the kidney with hemorrhagic shock. Heart failure is
attributable to highly vascular metastases with arteriovenous communications analogous to those observed in Paget disease. 14 Spontaneous rupture produces massive retroperitoneal hemorrhage closely
resembling a ruptured aortic aneurysm and is equally
lethal. 15
Renal Complications of Extrarenal Malignancies
Space does not permit a detailed discussion of
the many abnormalities of renal function found in
subjects with malignant diseases; however, I shall
comment upon the fluid and electrolyte disorders
which frequently occur (Table 2), and discuss the
nephrotic syndrome associated with malignancy.
Hypercalcemia may result from bony metastases
or the forced immobilization of acutely ill patients.
Certain cases are the result of parathormone secreting
tumors which function autonomously, 16 and a growing number of reports have called attention to the
existence of prostaglandin-secreting tumors producing hypercalcemia which may be reversed with indomethacin.17 The hypercalcemia caused by both hormone-secreting tumors is reversible with complete
removal of the tumor. Persistence of hypercalcemia
after the primary tumor is excised may reflect the
other causes of hypercalcemia (see Table 2), or be the
result of metastases which, like the parent tumor, also
synthesize prostaglandins or parathormone.
Hypercalcemia, if severe, may have devastating
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TABLE 2
Electrolyte Abnormalities with Nonrenal Malignancies
I. HYPERCALCEMIA-producing severe volume depletion and functional renal failure , nephrolithiasis or nephrocalcinosis:
a. Metastases
b. Corticosteroid withdrawal/adrenal insufficiency
c. Prostaglandin-secreting tumors
d. Forced immobilization
e. Parathormone-secreting tumors

2. VOLUME DEPLETION AND HYPONATREMIA •-producing functional renal failure:
a. Hypoadrenalcorticism of tumor replacement, amyloidosis, surgical ablation of the adrenals, disseminated intra vascular coagulation
(DIC).
b. Excessive diuretic therapy for peritoneal metastases or mechanical edema.
c. Rapidly developing ascites and edema
d. Extrarehal electrolyte losses:secretory diarrheas, villous a denomas , drug Rx hyperemesis, intestin al obstruction, malabsorption and
carcinoid.
• To be distinguished from the syndrome of inappropriate ADH secretion (CNS tumor/ metastases, vasopressin-secreting tumors,
vincristine/ cyclophosphamide therapy, and tricyclic anticonvulsants) where renal function does not specifically become impaired.
3. VOLUME DEPLETION AND HYPERNATREMIA-with functional renal failure:
a. Diabetes insipidus of pituitary replacement, brain metastases, urinary outflow obstruction.
b. Impaired thirst mechanism-organic or functional results of cachectic illness.
c. Kaliopenic and hypercalcemic nephropathy
d . Nasogastric feeding-osmotic diuresis
4. KALIOPENIC NEPHROPATHY-with impaired concentrating capacity and susceptibility to pyelonephritis:
a. Pernicious gastrointestinal electrolyte loss (see section 2)
b. " ACTH"-producing tumors
c. Juxtaglomerular cell tumors
d. Improper diuretic therapy
e. Lysozymuric and nonlysozymuric leukemias

effects upon the kidney, producing severe volume
depletion and functional renal failure, nephrolithiasis
with infection and urinary outflow obstruction, or
severe tubulointerstitial disease due to nephrocalcinos1s.
Volume depletion and hyponatremia are frequent complications which plague the patient with
malignant disease. Generically, the concurrence of
volume depletion and hyponatremia reflects a state in
which both sodium and water are lost from the body
in large amounts but the net sodium loss exceeds the
water deficit. Causes include adrenal insufficiency
owing to tumor replacement, adrenal amyloidosis,
surgical ablation of the adrenals as a therapeutic
adjuvant, and disseminated intravascular coagulation. Ill-advised sodium restriction with vigorous
diuretic therapy in an attempt to minimize mechanical edema or ascites due to peritoneal metastases is a
reasonably common cause of hyponatremic volume
depletion. The rapid development of ascites and
edema in sodium-restricted patients is another cause.
Massive electrolyte losses may occur through the in-

testinal tract as a result of the hyperemesis associated
with cancer chemotherapy, the secretory diarrheas
[amine precursor uptake and decarboxylation
(APUD) syndromes], mucus-secreting intestinal
tumors, intestinal obstruction, or malabsorption.
Massive fluid losses may be seen in the carcinoid
syndrome. The severe volume depletion .attendant
upon these complications may produce major abnormalities in renal function unless corrected.
Hyponatremia may also be seen in the presence
of extracellular fluid volume expansion-the socalled syndrome of inappropriate antidiuretic hormone (ADH) secretion. Causes include vasopressinsecreting tumors (especially of lung), primary or
metastatic intracranial malignancies, vincristine or
cyclophosphamide therapy to retard tumor growth,
and \he tricyclic anticonvulsants .18
Volume depletion may coexist with hypernatremia for a variety of reasons. Diabetes insipidus
may result from tumor invasion of the pituitary
gland, intracranial metastases, or urinary outflow obstruction. Nasogastric feeding of concentrated solu-
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tions lacking in free water is a common cause of an
obligatory solute diuresis. Impaired thirst due to either organic brain disease or as a functional result of
a cachectic illness may contribute greatly to the development of hypernatremic volume depletion, a situation which is further aggravated if kaliopenic or hypercalcemic nephropathy is present.
Kaliopenic (hypokalemic) nephropathy is manifested by impaired concentrating capacity and an
increased susceptibility to pyelonephritis. It may result from pernicious gastrointestinal electrolyte
losses, hyperadrenal corticism secondary to an adrenocorticotropic hormone (ACTH)-producing tumor, juxtaglomerular cell tumors, or improper diuretic management. Major degrees of hypokalemia
may be seen in patients with leukemia, especially
those leukemias associated with lysozymuria. 19 Impaired concentrating capacity may well lead to serious volume depletion and secondary renal dysfunction.
Nonelectrolyte-related abnormalities of the urinary tract are listed in Table 3, but cannot be covered
in detail in this brief review.
Nephrotic Syndrome Associated with Malignancy
An increasing number of reports amply document the association of the nephrotic syndrome with
TABLE 3
Nonelectrolyte Renal Complications of Malignancies
I.
2.
3.
4.
5.
6.
7.
8.
9.

JO.
11 .
12.
13.
14.
15.
16.
17.
18.
19.
20.

Fanconi syndrome
Renal tubular acidosis
Hydronephrosis-obstructive renal failure
Renal amyloidosis
Urate nephropathy
Radiation nephritis
"Citrovorum rescue," antimetabolite nephropathy
Myeloma kidney
Renal hemorrhage, outflow obstruction
Cortical necrosis post-disseminated intravascular coagulation (DIC)
Tumor-related lupus erythematosus (especially with
lymphoma )
Renal vein/ arterial or vena caval occlusion
Vasomotor nephropathy-hemorrhage, sepsis, shock,
and so forth
Nephrolithiasis/ nephrocalcinosis
Obstruction of bladder outflow, ureters, or urethra by
tumor invasion
Renal invasion by metastases
Benign nephromegaly, etiology unknown
Retroperitoneal fibrosis/ tumor invasion, producing
ureteral obstruction
Nephrotic syndrome
Acute papillary necrosis, pyelonephritis

malignant tumors.20 Some cases are the result of
amyloidosis, others to renal venous outflow obstruction, and still others to probable immune mechanisms. Myeloma and lymphoproliferative disorders are
among the most common tumor-related causes of
amyloidosis, yet solid tumors also may cause amyloid
deposition if their course is not an accelerated one. 22
Invasion of the renal veins and vena cava by hypernephromas or other tumors, and compression of
venous structures by retroperitoneal nodes, tumor
mass, or retroperitoneal fibrosis may produce mechanical edema and marked proteinuria but are uncommon causes of the nephrotic syndrome.
Tumor-related nephrotic syndrome occurs with
some frequency in the absence of either amyloidosis
or venous obstruction, Hodgkin disease leading the
list of causes.21 Lymphosarcoma, chronic lymphocytic leukemia, and Burkitt lymphoma also have been
associated with frank nephrosis. 21 Of the solid tumors, bronchogenic carcinoma has been the most
often found. Malignancies of the stomach, colon,
breast, skin, ovary, oropharynx, and kidneys have
all been incriminated.
The majority of lymphoma-related cases have
shown minimal glomerular changes on biopsy or
postmortem study. Most other types of tumors have
produced membranous, proliferative or mixed membranous and proliferative lesions. Reversal of the
nephrotic syndrome after excision or chemotherapy
of the primary tumor has been observed by many
authors, the return of proteinuria signaling regrowth
of the malignancy 21
In this overview, I have tried to touch on the
highly complex interaction between carcinomatosis
and the kidney. The manifestations of this relationship are so diverse and numerous that it is well to
remember the adage, "Many a medical reputation
has been lost in the retroperitoneum." It is hoped
that continued awareness of the protean manifestations of tumors relating to the kidney will help to
preserve the reputations of all clinicians.
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